Theaflavin
Catalog No: CFN98597
Theaflavin is a suitable natural inhibitor against influenza A (H1N1) neuraminidase, which has anti-inflammatory, antioxidative, anti-mutagenic, anti-HSV-1, and anti-carcinogenic properties. Theaflavin is active in the prevention of fatty liver and obesity, it can significantly reduce lipid accumulation, suppress fatty acid synthesis, and stimulate fatty acid oxidation. Theaflavin inhibits LPS-Induced IL-6, MCP-1, and ICAM-1 expression in bone marrow-derived macrophages through the blockade of NF-κB and MAPK signaling pathways; it also protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
Theaflavin 3,3'-di-O-gallate
Catalog No: CFN99130
Theaflavin-3,3'-digallate(TF3), an inducer of oxidative stress, which has anti-inflammatory and cancer chemopreventive actions, it reduces tumor angiogenesis by downregulating HIF-1αand VEGF; suggests that TF3 might serve as a potential anti-angiogenic agent for cancer treatment. TF3 and lactic acid combinations can reduce Herpes Simplex Virus(HSV) infectivity.
Theaflavine-3,3'-digallate
Catalog No: CFN98598
Theaflavin-3,3'-digallate is a potent AMP-activated protein kinase (AMPK) activator with anti-adiposity activity in adipocytes, suggesting its potential application in functional foods and nutraceuticals for obesity management. Theaflavin-3,3'-digallate is also an inducer of oxidative stress and apoptosis, it has strong antioxidant and antiangiogenic activities, it inhibits the tube formation of endothelial cells via decreased both MMP-2 and MMP-9 activities in vitro. A combination microbicide containing theaflavin-3,3'-digallate and lactic acid can reduce herpes simplex virus (HSV) transmission. Theaflavin-3,3'-digallate may exert its anti-inflammatory and cancer chemopreventive actions by suppressing the activation of NFkappaB through inhibition of IkappaB kinase (IKK) activity. Theaflavin-3,3'-digallate can repress osteoclastogenesis and prevent wear debris-induced osteolysis via suppression of ERK pathway, it is a promising candidate for the treatment of osteoclast-related osteolytic diseases, such as wear debris-induced peri-implant osteolysis (PIO).
